Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. - Wikidata - awgldk - TriplyDB

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

http://www.wikidata.org/entity/Q46426098

about

Direct renin inhibitors for preventing the progression of diabetic kidney disease Antihypertensive agents for preventing diabetic kidney disease Non-immunosuppressive treatment for IgA nephropathy Antihypertensive treatment for kidney transplant recipients My approach to the treatment of scleroderma Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy Management of Membranous Nephropathy in Western Countries Recent advances in managing and understanding diabetic nephropathy 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses Hypertension in Chronic Glomerulonephritis Can Aliskiren be Considered as a New Novel Drug for Hypertension?Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade Reducing cardiorenal risk through combination therapy with a direct renin inhibitor Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Management of diabetic kidney disease: Recent advances Diabetic kidney disease: a report from an ADA Consensus Conference Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Improvements in the Management of Diabetic Nephropathy Renal autoregulation in health and disease Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria Renin-Angiotensin-aldosterone system in diabetes and hypertension Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC)Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study Renoprotective effects of long-term oral nicotine in a rat model of spontaneous proteinuria Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats Management standards for stable coronary artery disease in India.Management Protocols of stable coronary artery disease in India: Executive summary.Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.Management of Diabetic Nephropathy in the Elderly: Special Considerations.Comparing angiotensin II receptor blockers on benefits beyond blood pressure Therapeutic management of diabetic kidney disease.Clinical therapeutic strategies for early stage of diabetic kidney disease.

P2860

Q24198989-345FE405-1A49-482C-9C2E-66AE7C715CDD Q24202090-3FEBF24A-46F4-4762-8908-744DB30C8D81 Q24235956-A53FE0D7-98C3-4252-AB27-6C8944BDA3B3 Q24240164-51C8E18C-3EE4-4ADB-89E4-C55C649B5471 Q24618843-F9D7D72A-AE2F-4C8E-A24C-97ECDB6E8FD4 Q24650348-2B10E24D-3235-4BCC-B3AB-82A9AD6A2FF0 Q24650910-F6E275C9-CE52-4EFE-B0E6-A65FB37F8E90 Q24657470-53AC0B15-F367-4120-A6C6-0A2EC264C0F3 Q26740477-AFE546C9-CAA1-4E0D-B616-78A38995594D Q26745900-9C6F5764-CDAD-4CB0-910F-B9E61AFAAA24 Q26764784-40C2A910-367E-40C6-BB32-69B0DE1387BE Q26765228-2FDE3622-237B-4AD9-A5B8-4F87E184A302 Q26767278-2A62AD32-ABEA-41F8-BFBC-9E624F0B7079 Q26768702-EFCAB57B-01AE-4B14-903E-BA0F2C24986D Q26775106-5585FDDF-76C0-4231-B9D9-DB36C7F39CD2 Q26799443-C6E6ACAC-4F95-4634-9C3E-5308F2A6250E Q26851307-4BD00A08-892A-46A7-BBCF-D11C6F18D38B Q26863404-18DB44B2-DAA5-42A2-A014-3617C54BBD03 Q26865691-1A87801D-4B22-4BE2-81EB-7EBA852916F9 Q27007027-50BE6F7E-59D1-4554-B092-5BE6CF43CF1F Q27009775-CC34B1D9-EAFA-4BCF-9C35-C9A668C74E5E Q27012546-2804D2A0-2727-4AC0-A2AA-A3CCAEFE3E02 Q27687851-6A14E8EA-D2E1-4826-9EF6-CE6F02E46FE7 Q28080717-7DFB0BC5-BF13-4C30-B11A-BE41C2B01C3C Q28082365-A673677B-4501-45DB-AD00-4CF4B85D7479 Q28085248-B8B9D0A5-CBF4-4028-9287-882DDD4E59DB Q28308222-C9CB1745-35EB-419C-82A3-0CD6CB3ECEF7 Q28387627-90C92669-547B-419F-8265-5DFE21E22C88 Q28482185-F3B25808-8C7A-41AB-A812-507C30E59CB1 Q28566503-17EA7015-EA36-4E34-A5DA-A316F80FD908 Q28583340-FAABA11F-6D20-40CB-B88C-A7A1826AB518 Q28748219-0F17CA3D-2FC7-4F37-949D-983AD1E43936 Q28828825-0A4E75AB-F034-4E64-86C9-1821AD8950BF Q30239853-0559A45B-947A-4266-823F-8019DF14D7A9 Q30240155-15BBD43E-474B-424B-A030-637F2B80E390 Q30251988-F1EDB123-8C43-4846-BB68-780FBCC8514E Q30353386-AD63DF22-A810-4B49-98B8-2C7AF2504F85 Q30360678-3CB56FFD-D601-448F-9CAD-DB80C2D18B14 Q30362729-99989FB2-2DBC-4F7D-97FF-5A053C9C5617 Q30363683-A0821E63-FB92-4C87-BC0D-95AAB6739EC4

P2860

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

http://www.wikidata.org/entity/Q46426098

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@en

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@nl

type

label

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@en

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@nl

prefLabel

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@en

Renal outcomes with telmisarta ...... ouble-blind, controlled trial.

@nl

P1433

Q46426098-AAED7570-CF5C-46A1-A26D-563454DC61B4

P1476

Q46426098-10A751F8-6F68-4F6C-BD13-1FEB4D418ED7

P2093

Q46426098-042AAE16-42B5-4662-8E69-307348A40C39

Q46426098-0C2E6018-6526-4176-8CB7-C93ACC47CB21

Q46426098-2D373B0B-49FB-41A4-A328-238CC28165EA

Q46426098-4ED9A3CC-428A-4123-8F2A-A579BCA91A90

Q46426098-4FEC8BBC-AD66-41C0-A5A1-EBFE7F4AF945

Q46426098-634F13A4-2E7E-4C73-822B-0FA50EC2554C

Q46426098-815BE110-0C99-4C20-89F6-B393F03B6316

Q46426098-8F4304FC-7EF7-4C6D-AA03-C67325524F15

Q46426098-9B87D69F-7D4F-45BD-A8D4-73C19F7CA897

Q46426098-B38E8AE5-11B8-42CA-B1FA-3E555D4C8855

P304

Q46426098-19E94382-3996-4744-BE11-BB98B369652D

P31

Q46426098-B6FC54F3-FE49-4070-8F16-691F3171C427

P356

Q46426098-01746BFD-5684-4907-9A54-3DCCF3EA102C

P407

Q46426098-62301C7B-42AA-4649-9175-766B13DB2EC4

P433

Q46426098-8AF34CDF-0384-4988-B5B0-7EB08FBD90A8

P478

Q46426098-C089693F-8220-4869-BD21-8F2BB505A86B

P50

Q46426098-0B80559A-FE9C-497C-8457-3DB0FFFCEA2D

Q46426098-3B849CB6-47E1-461E-84B6-6EAE8017A83E

Q46426098-64C9EDA6-B540-4B1B-B90B-2E681F0CC309

Q46426098-655780A6-B1B9-432C-A856-6F629912F997

Q46426098-BF75E5F7-43B1-468A-9D02-5E612FE0D294

P577

Q46426098-60577D39-0274-4873-8A0D-5B2135D14BC7

P698

Q46426098-512C7BA9-245F-4024-A0C7-A3B5D3B4AC0B

P356

S0140-6736(08)61236-2

P1433

P1476

Renal outcomes with telmisarta ...... double-blind, controlled trial

@en

P2093

Aldo Maggioni

http://www.w3.org/2001/XMLSchema#string

Alexander Parkhomenko

http://www.w3.org/2001/XMLSchema#string

Ali Oto

http://www.w3.org/2001/XMLSchema#string

Helmut Schumacher

http://www.w3.org/2001/XMLSchema#string

Johannes F E Mann

http://www.w3.org/2001/XMLSchema#string

Kaj Metsärinne

http://www.w3.org/2001/XMLSchema#string

Koon K Teo

http://www.w3.org/2001/XMLSchema#string

Leanne Dyal

http://www.w3.org/2001/XMLSchema#string

Matthew McQueen

http://www.w3.org/2001/XMLSchema#string

Matyas Keltai

http://www.w3.org/2001/XMLSchema#string

P304

547-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(08)61236-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

9638

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth Dickstein

Leopoldo S. Piegas

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18707986

http://www.w3.org/2001/XMLSchema#string